Enanta price target raised to $25 from $24 at Citizens JMP

Citizens JMP raised the firm’s price target on Enanta (ENTA) to $25 from $24 and keeps an Outperform rating on the shares. Enanta Pharmaceuticals expects cash and continuing Mavyret income to fund operations into fiscal 2028, the analyst tells investors in a research note.